THERAMEX
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.
Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.
“Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise. We are delighted to be entering into this partnership with Radius, building on our expanding portfolio and aligning missions to reduce fracture risks for many postmenopausal women suffering from osteoporosis.” - Rob Stewart, CEO of Theramex
“We are thrilled to have Theramex bring abaloparatide to postmenopausal women in Europe who could benefit from this impactful treatment. Our aligned, strategic vision of bringing effective solutions to the right patient gives us unwavering confidence in this partnership. We look forward to seeing the continued global expansion of abaloparatide to patients with osteoporosis worldwide.” - Scott Briggs, CEO of Radius
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause, and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.
www.theramex.com
About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the treatment of men with osteoporosis at high risk for fracture.
ELADYNOS®(abaloparatide) injection was approved by the European Medicines Agency for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapies. This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines.
www.radiuspharm.com
FOR MEDIA AND INVESTORS ONLY
ELAD_HQ_PRESSR_009443 D.O.P 8/3/23
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005585/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chelsea Football Club and FPT Elevate and Expand Partnership to Principal Status22.10.2025 11:12:00 CEST | Press release
Chelsea Football Club and FPT today announce an expansion to their existing partnership, which sees Asia Pacific’s most successful technology solutions provider named as a Principal Partner for the 2025/26 season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251017778664/en/ As a Principal Partner, FPT will be represented on the sleeves of the Chelsea FC men’s, women’s, and academy kits. The market-leading digital technology solutions provider FPT and Chelsea FC first joined forces earlier this year in a new and innovative collaboration to transform the club’s digital capabilities and enhance the club’s fan engagement, bringing fans from across the world closer to the club. Through several technology workshops at FPT’s innovation campus in Vietnam, Chelsea FC and FPT have identified and built a transformation roadmap that covers Digital Platforms, Customer Engagement, Business Operations, and Emerging Technologies. With a
Paymentology Launches PayCredit to Power Credit Innovation for Digital Banks and Fintechs22.10.2025 10:00:00 CEST | Press release
The new credit solution integrates card issuing and credit ledger management, helping issuers reduce complexity and accelerate time to market. Paymentology, the leading global issuer-processor, has launched PayCredit, an advanced credit ledger platform designed to help financial institutions deliver tailored, feature rich credit products at speed, overcoming the limitations of legacy and core banking systems. Amid rising demand for flexible financial payment tools, credit cards remain a critical instrument for enabling consumer spending, managing cash flow, and deepening customer loyalty. Yet many legacy credit systems lack the flexibility to meet the expectations of today's consumers, who demand a combination of both revolving and instalment credit to help them better manage their money, whilst many modern ledgers are retrofitted from a debit architecture and struggle to provide credit processing. PayCredit was developed from the ground up with credit billing cycles and logic at its c
Infrastructure Capital Advisors Expands its Offerings into European Markets With Launch of Preferred Income UCITS ETF (PFFI) & Declares The Fund’s First Dividend22.10.2025 10:00:00 CEST | Press release
PFFI is now listed on the LSE, Xetra and Borsa Italiana Exchanges and registered in 11 European markets Infrastructure Capital Advisors (“Infrastructure Capital”), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is celebrating the expansion of its offerings into Europe with the launch of the Infrastructure Capital Preferred Income UCITS ETF (PFFI). This actively managed ETF, which was listed in September, seeks to produce diversified income by targeting high yield income investments by predominately focusing on preferred stocks. Today,PFFI is also declaring its first dividend of $0.1335 per share ($1.602 per share on an annualized basis). The dividend will be paid on November 3, 2025 to shareholders of record as of the close of business on October 29, 2025. “We are thrilled to offer investors across a range of global markets the opportunity to benefit from our team’s active management process applied to preferred and income
Locus Robotics Reports Record Growth Achieving 6 Billion Picks in Fastest Time Yet22.10.2025 10:00:00 CEST | Press release
Accelerating adoption, rapid customer ROI, and consecutive record quarters fuel positive market momentum Locus Robotics, the global leader in AI-driven, mobile warehouse automation, today announced its strongest growth over the past two quarters, reflecting accelerating industry adoption of Physical AI, seamlessly fusing intelligent robotics and real-world execution. Driven by surging implementations and faster time-to-value for customers, Locus Robotics recently surpassed 6 billion picks worldwide, with the last billion in just 24 weeks—the fastest pace in its history. “Our growth is driven by our customers’ success,” said Rick Faulk, CEO of Locus Robotics. “Retailers, 3PLs, and healthcare providers are seeing measurable impact faster than ever—scaling productivity in weeks, not months. Staples Canada, for example, hit one million picks just 70 days after going live, proving the immediate ROI our platform delivers.” So far this year, Locus Robotics has seen 30–40% year-over-year volum
Smartstream and ActiveViam Collaborate to Meet Demands for Collateral Optimisation22.10.2025 09:55:00 CEST | Press release
Key Facts Smartstream and ActiveViam have partnered to deliver an integrated solution combining Smartstream’s Smart Collateral with ActiveViam’s Atoti Collateral Optimisation platform. The collaboration enables financial institutions to optimise collateral allocation, reduce reliance on costly liquidity buffers, and achieve immediate return on investment. The modular, high-performance solution supports regulatory compliance (UMR, EMIR, Basel III) and empowers clients to make smarter use of their collateral inventory. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the partnership with ActiveViam, a global provider of advanced data analytics and decision-making solutions for financial services – together the two companies will provide immediate ROI for collateral management optimisation, for clients in treasury and capital markets. This collaboration connects two technologies, Smartstream’s Smart Collateral with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom